Concepedia

Janusz Mezynski

JM

3

Publications

295

Citations

3

H-Index

2012

Active since

Affiliations

Institute of Cancer Research(Current)

Janusz Mezynski is an author at Institute of Cancer Research specializing in pharmacotherapy, medicine, and pharmacology.

Top concepts

MedicinePharmacologyPharmacotherapyOncologyCancer TherapyDrug DiscoveryOvarian CancerDrug ResistanceMolecular OncologyRadiation Oncology

Publications per year

2012–2018

3

Publications

3

Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?

Janusz Mezynski, Carmel Pezaro, Diletta Bianchini et al. · Annals of Oncology · 2012 · 246 citations

Metronomic Therapy, Pharmacology, Clinical Evidence +7

A phase I dose escalation study of oral MK-2206 (allosteric Akt inhibitor) with oral selumetinib (AZD6244; ARRY-142866) (MEK 1/2 inhibitor) in patients with advanced or metastatic solid tumors.

Khurum Khan, Li Yan, Janusz Mezynski et al. · Journal of Clinical Oncology · 2012 · 36 citations

Medicine, Kras Mutation, Metronomic Therapy +13

Frequency, impact and a preclinical study of novel <i>ERBB</i> gene family mutations in HER2-positive breast cancer

Naomi Elster, Sinéad Toomey, Yue Fan et al. · Therapeutic Advances in Medical Oncology · 2018 · 13 citations · Full text

Rows per page

1–3 of 3